Management of systemic lupus erythematosus in Chinese patients

References

• Petri M. Epidemiology of systemic lupus erythematosus. Best Pract. Res. Clin. Rheumatol.16, 847–858 (2002).
   PubMed Web of Science ®Google Scholar
• Mok CC, Lau CS. Lupus in Hong Kong Chinese. Lupus12, 717–722 (2003).
   PubMedGoogle Scholar
• Mok CC, Mak A, Chu WP, To CH, Wong SN. Long term survival of southern Chinese patients with systemic lupus erythematosus: a prospective study of all age groups. Medicine (Baltimore)84, 218–224 (2005).
   PubMed Web of Science ®Google Scholar
• Mok CC, Tang SS, To CH, Petri M. Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups. Arthritis Rheum.52, 2774–2782 (2005).
   PubMed Web of Science ®Google Scholar
• Abu-Shakra M, Urowitz MB, Gladman DD, Gough J. Mortality studies in systemic lupus erythematosus. Results from a single center. I. Causes of death. J. Rheumatol.22, 1259–1264 (1995).
   PubMed Web of Science ®Google Scholar
• Urowitz MB, Gladman DD, Abu-Shakra M, Farewell VT. Mortality studies in systemic lupus erythematosus. Results from a single center. III. Improved survival over 24 years. J. Rheumatol.24, 1061–1065 (1997).
   PubMed Web of Science ®Google Scholar
• Cervera R, Khamashta MA, Font J et al; European Working Party on Systemic Lupus Erythematosus. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore)82, 299–308 (2003).
   PubMed Web of Science ®Google Scholar
• Mok CC, Lee KW, Ho CTK, Lau CS, Wong RWS. A prospective study of survival and prognostic indicators of systemic lupus erythematosus in a southern Chinese population. Rheumatology (Oxford)39, 399–406 (2000).
   PubMed Web of Science ®Google Scholar
• Peschken CA, Esdaile JM. Systemic lupus erythematosus in North American Indians: a population based study. J. Rheumatol.27, 1884–1891 (2000).
   PubMed Web of Science ®Google Scholar
• Gourley MF, Austin HA 3rd, Scott D et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann. Intern. Med.125, 549–557 (1996).
   PubMed Web of Science ®Google Scholar
• Petri M. Infection in systemic lupus erythematosus. Rheum. Dis. Clin. North Am.24, 423–456 (1998).
   PubMed Web of Science ®Google Scholar
• Mok CC, Ho CTK, Chan KW, Lau CS, Wong RWS. Outcome and prognostic indicators of diffuse proliferative lupus glomerulonephritis treated with sequential oral cyclophosphamide and azathioprine. Arthritis Rheum.46, 1003–1013 (2002).
   PubMed Web of Science ®Google Scholar
• Houssiau FA, Vasconcelos C, D’Cruz D et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum.50, 3934–3940 (2004).
   PubMed Web of Science ®Google Scholar
• Mok CC, Ying KY, Ng WL et al. Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide. Am. J. Med.119, 355 e25–e33 (2006).
   Google Scholar
• Jayne D, Rasmussen N, Andrassy K et al; European Vasculitis Study Group. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N. Engl. J. Med.349, 36–44 (2003).
   PubMed Web of Science ®Google Scholar
• Abu-Shakra M, Zalmanson S, Neumann L, Flusser D, Sukenik S, Buskila D. Influenza virus vaccination of patients with systemic lupus erythematosus: effects on disease activity. J. Rheumatol.27, 1681–1685 (2000).
   PubMed Web of Science ®Google Scholar
• Mok CC, Lai KN. Mycophenolate mofetil in lupus glomerulonephritis. Am. J. Kidney Dis.40, 447–457 (2002).
   PubMed Web of Science ®Google Scholar
• Mak A, Mok CC. Mycophenolate mofetil for refractory haemolytic anemia in systemic lupus erythematosus. Lupus14, 856–858 (2005).
   PubMed Web of Science ®Google Scholar
• Schanz S, Ulmer A, Rassner G, Fierlbeck G. Successful treatment of subacute cutaneous lupus erythematosus with mycophenolate mofetil. Br. J. Dermatol.147, 174–178 (2002).
   PubMed Web of Science ®Google Scholar
• Mok CC, Mak A, To CH. Mycophenolate mofetil for lupus-related myelopathy. Ann. Rheum. Dis.65, 971–973 (2006).
   PubMed Web of Science ®Google Scholar
• Mok CC. Mycophenolate mofetil for non-renal manifestations of systemic lupus erythematosus: a systematic review. Scand. J. Rheumatol. (in press).
   Google Scholar
• Briggs WA, Choi MJ, Scheel PJ Jr. Successful mycophenolate mofetil treatment of glomerular disease. Am. J. Kidney Dis.31, 213–217 (1998).
   PubMed Web of Science ®Google Scholar
• Glicklich D, Acharya A. Mycophenolate mofetil therapy for lupus nephritis refractory to intravenous cyclophosphamide. Am. J. Kidney Dis.32, 318–322 (1998).
   PubMed Web of Science ®Google Scholar
• Buratti S, Szer IS, Spencer CH, Bartosh S, Reiff A. Mycophenolate mofetil treatment of severe renal disease in pediatric onset systemic lupus erythematosus. J. Rheumatol.28, 2103–2108 (2001).
   PubMed Web of Science ®Google Scholar
• Dooley MA, Cosio FG, Nachman PH et al. Mycophenolate mofetil therapy in lupus nephritis: clinical observations. J. Am. Soc. Nephrol.10, 833–839 (1999).
   PubMed Web of Science ®Google Scholar
• Karim MY, Pisoni CN, Ferro L et al. Reduction of proteinuria with mycophenolate mofetil in predominantly membranous lupus nephropathy. Rheumatology (Oxford)44, 1317–1321 (2005).
   PubMed Web of Science ®Google Scholar
• Kapitsinou PP, Boletis JN, Skopouli FN, Boki KA, Moutsopoulos HM. Lupus nephritis: treatment with mycophenolate mofetil. Rheumatology (Oxford)43, 377–380 (2004).
   PubMed Web of Science ®Google Scholar
• Chan TM, Li FK, Tang CS et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong–Guangzhou Nephrology Study Group. N. Engl. J. Med.343, 1156–1162 (2000).
   PubMed Web of Science ®Google Scholar
• Ong LM, Hooi LS, Lim TO et al. Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrology (Carlton)10, 504–510 (2005).
   PubMed Web of Science ®Google Scholar
• Ginzler EM, Dooley MA, Aranow C et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N. Engl. J. Med.353, 2219–2228 (2005).
   PubMed Web of Science ®Google Scholar
• Contreras G, Pardo V, Leclercq B et al. Sequential therapies for proliferative lupus nephritis. N. Engl. J. Med.350, 971–980 (2004).
   PubMed Web of Science ®Google Scholar
• Tam LS, Li EK, Leung CB et al. Long-term treatment of lupus nephritis with cyclosporin A. QJM91, 573–580 (1998).
   PubMed Web of Science ®Google Scholar
• Tam LS, Li EK, Szeto CC et al. Treatment of membranous lupus nephritis with prednisone, azathioprine and cyclosporin A. Lupus10, 827–829 (2001).
   PubMedGoogle Scholar
• Hallegua D, Wallace DJ, Metzger AL, Rinaldi RZ, Klinenberg JR. Cyclosporine for lupus membranous nephritis: experience with ten patients and review of the literature. Lupus9, 241–251 (2000).
   PubMed Web of Science ®Google Scholar
• Politt D, Heintz B, Floege J, Mertens PR. Tacrolimus- (FK 506) based immunosuppression in severe systemic lupus erythematosus. Clin. Nephrol.62, 49–53 (2004).
   PubMed Web of Science ®Google Scholar
• Mok CC, Tong KH, To CH, Siu YP, Au TC. Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: an open-labeled pilot study. Kidney Int.68, 813–817 (2005).
   PubMed Web of Science ®Google Scholar
• Remer CF, Weisman MH, Wallace DJ. Benefits of leflunomide in systemic lupus erythematosus: a pilot observational study. Lupus10, 480–483 (2001).
   PubMed Web of Science ®Google Scholar
• Petera P, Mander B, Manger K et al. A pilot study of leflunomide in systemic lupus erythematosus. Arthritis Rheum.48, S241 (2001).
   Google Scholar
• Tam LS, Li EK, Wong CK, Lam CW, Szeto CC. Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus. Lupus13, 601–604 (2004).
   PubMed Web of Science ®Google Scholar
• Gensburger D, Kawashima M, Marotte H, Kanitakis J, Miossec P. Lupus erythematosus with leflunomide: induction or reactivation? Ann. Rheum. Dis.64, 153–155 (2005).
   PubMed Web of Science ®Google Scholar
• Goeb V, Berthelot JM, Joly P et al. Leflunomide-induced subacute cutaneous lupus erythematosus. Rheumatology (Oxford)44, 823–824 (2005).
   PubMed Web of Science ®Google Scholar
• Van Vollenhoven RF, Engleman EG, McGuire JL. An open study of dehydroepiandrosterone in systemic lupus erythematosus. Arthritis Rheum.37, 1305–1310 (1994).
   PubMed Web of Science ®Google Scholar
• Van Vollenhoven RF, Engleman EG, McGuire JL. Dehydroepiandrosterone in systemic lupus erythematosus: results of a doubleblind, placebo-controlled, randomized clinical trial. Arthritis Rheum.38, 1826–1831 (1995).
   PubMed Web of Science ®Google Scholar
• Petri MA, Lahita RG, Van Vollenhoven RF et al; for the GL701 Study Group. Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum.46, 1820–1829 (2002).
   PubMed Web of Science ®Google Scholar
• Chang DM, Lan JL, Lin HY, Luo SF. Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: a multicenter randomized, double-blind, placebo-controlled trial. Arthritis Rheum.46, 2924–2927 (2002).
   PubMed Web of Science ®Google Scholar
• Petri MA, Mease PJ, Merrill JT et al. Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus. Arthritis Rheum.50, 2858–2868 (2004).
   PubMed Web of Science ®Google Scholar
• Boumpas DT, Tassiulas IO, Fleisher TA et al. A pilot study of low-dose fludarabine in membranous nephropathy refractory to therapy. Clin. Nephrol.52, 67–75 (1999).
   PubMed Web of Science ®Google Scholar
• Davis JC Jr, Austin H 3rd, Boumpas D et al. A pilot study of 2-chloro-2´-deoxyadenosine in the treatment of systemic lupus erythematosus-associated glomerulonephritis. Arthritis Rheum.41, 335–343 (1998).
   PubMed Web of Science ®Google Scholar
• Leandro MJ, Cambridge G, Edwards JC, Ehrenstein MR, Isenberg DA. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford)44, 1542–1545 (2005).
   PubMed Web of Science ®Google Scholar
• Marks SD, Patey S, Brogan PA et al. B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus. Arthritis Rheum.52, 3168–3174 (2005).
   PubMed Web of Science ®Google Scholar
• Gottenberg JE, Guillevin L, Lambotte O et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann. Rheum. Dis.64, 913–920 (2005).
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Gunnarsson I, Welin-Henriksson E et al. Biopsy-verified response of severe lupus nephritis to treatment with rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to cyclophosphamide alone. Scand. J. Rheumatol.33, 423–427 (2004).
   PubMed Web of Science ®Google Scholar
• Vigna-Perez M, Hernandez-Castro B, Paredes-Saharopulos O et al. Clinical and immunological effects of rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res. Ther.8, R83 (2006).
   PubMed Web of Science ®Google Scholar
• Looney RJ, Anolik JH, Campbell D et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a Phase I/II dose-escalation trial of rituximab. Arthritis Rheum.50, 2580–2589 (2004).
   PubMed Web of Science ®Google Scholar
• Lambotte O, Durbach A, Kotb R, Ferlicot S, Delfraissy JF, Goujard C. Failure of rituximab to treat a lupus flare-up with nephritis. Clin. Nephrol.64, 73–77 (2005).
   PubMed Web of Science ®Google Scholar
• Edelbauer M, Jungraithmayr T, Zimmerhackl LB. Rituximab in childhood systemic lupus erythematosus refractory to conventional immunosuppression: case report. Pediatr. Nephrol.20, 811–813 (2005).
   PubMed Web of Science ®Google Scholar
• Cartron G, Dacheux L, Salles G et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood99, 754–758 (2002).
   PubMed Web of Science ®Google Scholar
• Anolik JH, Campbell D, Felgar RE et al. The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum.48, 455–459 (2003).
   PubMed Web of Science ®Google Scholar
• Tsutsumi Y, Kawamura T, Saitoh S et al. Hepatitis B virus reactivation in a case of non-Hodgkin’s lymphoma treated with chemotherapy and rituximab: necessity of prophylaxis for hepatitis B virus reactivation in rituximab therapy. Leuk. Lymphoma45, 627–629 (2004).
   PubMed Web of Science ®Google Scholar
• Polyak MJ, Deans JP. Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure. Blood99, 3256–3262 (2002).
   PubMed Web of Science ®Google Scholar
• Ocrelizumab. Roche Investigator’s Brochure (2007).
   Google Scholar
• Kaufmann J, Wegener WA, Horak ID et al. Initial clinical study of immunotherapy in SLE using epratuzumab (humanized anti-CD22 antibody). Arthritis Rheum.49 (2004) (Abstract 1127).
   Google Scholar
• Furie R, Stohl W, Ginzler E et al. Safety, pharmacokinetic and pharmacodynamic results of a phase 1 single and double doseescalation study of Lymphostat-B (human monoclonal antibody to BLyS) in SLE patients. Arthritis Rheum.48 (2003) (Abstract 922).
   Google Scholar
• Wallace DJ, Lisse J, Stohl W et al.; LBSL02 Study Group. Presented at: American College of Rheumatology meeting, Washington, DC, USA, 10–16 November, 2006 (Abstract 2012).
   Google Scholar
• Furie RA, Cash JM, Cronin ME et al. Treatment of systemic lupus erythematosus with LJP 394. J. Rheumatol.28, 257–265 (2001).
   PubMed Web of Science ®Google Scholar
• Alarcon-Segovia D, Tumlin JA, Furie RA et al. LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study. Arthritis Rheum.48, 442–454 (2003).
   PubMed Web of Science ®Google Scholar
• Finck BK, Linsley PS, Wofsy D. Treatment of murine lupus with CTLA4Ig. Science265, 1225–1227 (1994).
   PubMed Web of Science ®Google Scholar
• Daikh DI, Wofsy D. Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide. J. Immunol.166, 2913–2916 (2001).
   PubMed Web of Science ®Google Scholar
• Genovese MC, Becker JC, Schiff M et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition. N. Engl. J. Med.353, 1114–1123 (2005).
   PubMed Web of Science ®Google Scholar
• Daikh DI, Finck BK, Linsley PS, Hollenbaugh D, Wofsy D. Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways. J. Immunol.159, 3104–3108 (1997).
   PubMed Web of Science ®Google Scholar
• Davis JC Jr, Totoritis MC, Rosenberg J, Sklenar TA, Wofsy D. Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus. J. Rheumatol.28, 95–101 (2001).
   PubMed Web of Science ®Google Scholar
• Kalunian KC, Davis JC Jr, Merrill JT, Totoritis MC, Wofsy D; IDEC-131 Lupus Study Group. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum.46, 3251–3258 (2002).
   PubMed Web of Science ®Google Scholar
• Boumpas DT, Furie R, Manzi S et al; BG9588 Lupus Nephritis Trial Group. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum.48, 719–727 (2003).
   PubMed Web of Science ®Google Scholar
• Ishida H, Muchamuel T, Sakaguchi S, Andrade S, Menon S, Howard M. Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice. J. Exp. Med.179, 305–310 (1994).
   PubMed Web of Science ®Google Scholar
• Llorente L, Richaud-Patin Y, Garcia-Padilla C et al. Clinical and biological effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum.43, 1790–1800 (2000).
   PubMed Web of Science ®Google Scholar
• Anolik JH, Aringer M. New treatments for SLE: cell-depleting and anti-cytokine therapies. Best Pract. Res. Clin. Rheumatol.19, 859–878 (2005).
   PubMed Web of Science ®Google Scholar
• Aringer M, Graninger WB, Steiner G, Smolen JS. Safety and efficacy of tumor necrosis factor α blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum.50, 3161–3169 (2004).
   PubMed Web of Science ®Google Scholar
• Linker-Israeli M, Deans RJ, Wallace DJ, Prehn J, Ozeri-Chen T, Klinenberg JR. Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis. J. Immunol.147, 117–123 (1991).
   PubMed Web of Science ®Google Scholar
• Finck BK, Chan B, Wofsy D. Interleukin 6 promotes murine lupus in NZB/NZW F1 mice. J. Clin. Invest.94, 585–591 (1994).
   PubMed Web of Science ®Google Scholar
• Mihara M, Takagi N, Takeda Y, Ohsugi Y. IL-6 receptor blockage inhibits the onset of autoimmune kidney disease in NZB/W F1 mice. Clin. Exp. Immunol.112, 397–402 (1998).
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Miyasaka N, Yamamoto K et al. Consistent clinical response resulted from three Japanese randomized controlled trials of tocilizumab, a humanized anti-IL6 receptor antibody, in active rheumatoid arthritis patients. Presented at: American College of Rheumatology Meeting, Washington, DC, USA, 10–16 November, 2006 (Abstract 945).
   Google Scholar
• Illei GG, Yarboro C, Shirota Y et al. Tocilizumab (humanized anti-IL-6 receptor monoclonal antibody) in patients with systemic lupus erythematosus (SLE): safety, tolerability and preliminary efficacy. Presented at: American College of Rheumatology Meeting, Washington, DC, USA, 10–16 November, 2006 (Abstract L20).
   Google Scholar
• Wang Y, Hu Q, Madri JA, Rollins SA, Chodera A, Matis LA. Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. Proc. Natl Acad. Sci. USA93, 8563–8568 (1996).
   PubMed Web of Science ®Google Scholar
• Rother RP, Mojcik CF, McCroskery EW. Inhibition of terminal complement: a novel therapeutic approach for the treatment of systemic lupus erythematosus. Lupus13, 328–34 (2004).
   PubMed Web of Science ®Google Scholar
• Sthoeger ZM, Dayan M, Tcherniack A et al. Modulation of autoreactive responses of peripheral blood lymphocytes of patients with systemic lupus erythematosus by peptides based on human and murine anti-DNA autoantibodies. Clin. Exp. Immunol.131, 385–392 (2003).
   PubMed Web of Science ®Google Scholar
• Luger D, Dayan M, Zinger H et al. A peptide based on the complementarity determining region 1 of a human monoclonal autoantibody ameliorates spontaneous and induced lupus manifestations in correlation with cytokine immunomodulation. J. Clin. Immunol.24, 579–590 (2004).
   PubMed Web of Science ®Google Scholar
• Sharabi A, Azulai H, Sthoeger ZM, Mozes E. Clinical amelioration of murine lupus by a peptide based on the complementarity determining region-1 of an autoantibody and by cyclophosphamide: similarities and differences in the mechanisms of action. Immunology121, 248–257 (2007).
   PubMed Web of Science ®Google Scholar
• Pavletic SZ, Illei GG. The role of immune ablation and stem cell transplantation in severe SLE. Best Pract. Res. Clin. Rheumatol.19, 839–858 (2005).
   PubMed Web of Science ®Google Scholar
• Jayne D, Passweg J, Marmont A et al. Autologous stem cell transplantation for systemic lupus erythematosus. Lupus13, 168–176 (2004).
   PubMed Web of Science ®Google Scholar
• Brodsky RA, Petri M, Smith BD et al. Immunoablative high-dose cyclophosphamide without stem-cell rescue for refractory, severe autoimmune disease. Ann. Intern. Med.129, 1031–1035 (1998).
   PubMed Web of Science ®Google Scholar
• Petri M, Jones RJ, Brodsky RA. High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus. Arthritis Rheum.48, 166–173 (2003).
   PubMed Web of Science ®Google Scholar
• Petri M, Brodsky R, Jones R, Gladstone D, Fillius M, Magder L. High-dose cyclophosphamide vs monthly (NIH) cyclophosphamide: final results. Presented at: American College of Rheumatology Meeting, Washington, DC, USA, 10–16 November, 2006 (Abstract 1038).
   Google Scholar
• Mok CC, Lau CS, Wong RWS. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy. Arthritis Rheum.41, 831–837 (1998).
   PubMed Web of Science ®Google Scholar
• Somers EC, Marder W, Christman GM et al. Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus. Arthritis Rheum.52, 2761–2767 (2005).
   PubMed Web of Science ®Google Scholar
• Ramsey-Goldman R, Dunn JE, Huang CF et al. Frequency of fractures in women with systemic lupus erythematosus: comparison with United States population data. Arthritis Rheum.42, 882–890 (1999).
   PubMedGoogle Scholar
• Yee CS, Crabtree N, Skan J et al. Prevalence and predictors of fragility fractures in systemic lupus erythematosus. Ann. Rheum. Dis.64, 111–113 (2005).
   PubMedGoogle Scholar
• Mok CC, Mak A, Ma KM. Bone mineral density in postmenopausal Chinese patients with systemic lupus erythematosus. Lupus14, 106–112 (2005).
   PubMedGoogle Scholar
• Kanis JA, Johnell O, Black DM et al. Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial. Bone33, 293–300 (2003).
   PubMed Web of Science ®Google Scholar
• Barrett-Connor E, Grady D, Sashegyi A et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA287, 847–857 (2002).
   PubMed Web of Science ®Google Scholar
• Mok CC, To CH, Mak A, Ma KM. Raloxifene for postmenopausal women with systemic lupus erythematosus: a pilot randomized controlled study. Arthritis Rheum.52, 3997–4002 (2005).
   PubMed Web of Science ®Google Scholar